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Abstract 
Noroviruses are the most common cause of acute viral gastroenteritis, accounting for 
>21 million cases annually in the U.S. alone. Norovirus infections constitute an 
important health problem for which there are no specific antiviral therapeutics or 
vaccines. In this study, a series of bisulfite adducts derived from representative 
transition state inhibitors (dipeptidyl aldehydes and α-ketoamides) was synthesized and 
shown to exhibit anti-norovirus activity in a cell-based replicon system. The ED50 of the 
most effective inhibitor was 60 nM. This study demonstrates for the first time the 
utilization of bisulfite adducts of transition state inhibitors in the inhibition of norovirus 
3CL protease in vitro and in a cell-based replicon system. The approach described 
herein can be extended to the synthesis of the bisulfite adducts of other classes of 
transition state inhibitors of serine and cysteine proteases, such as α-ketoheterocycles, 
α-ketoesters, and others.  
 
 
 
 
 
 
 
 
 
    Noroviruses are a major cause of waterborne and foodborne acute gastroenteritis.1-4 
Outbreaks of viral gastroenteritis are common because of the highly contagious nature 
of noroviruses. Noroviral gastroenteritis is the cause of significant morbidity and may 
lead to fatal infection in children, the elderly, and immuno-compromised individuals.5 
There are currently no effective vaccines or antiviral agents for combating norovirus 
infection; consequently, there is an urgent need for the discovery of small molecule 
therapeutics for the management and treatment of norovirus infection.6-7 Recently-
reported small molecule norovirus inhibitors include cyclic and acyclic sulfamide 
derivatives,8-10 piperazine derivatives,11 pyranobenzopyrones,12 nitazoxanide,13 and 
other chemotypes.14 
    The norovirus RNA genome encodes a polyprotein which is processed by a virus-
encoded 3C-like cysteine protease (3CLpro) to generate mature non-structural 
proteins.15 Co- and post-translational processing of the polyprotein by norovirus 3CLpro 
is essential for virus replication; consequently, norovirus 3CLpro is an attractive target 
for the discovery of anti-norovirus small molecule therapeutics.  
   We have recently demonstrated that peptidyl aldehydes,16 α-ketoamides,17 and α-
ketoheterocycles17 potently inhibit norovirus 3CLpro in vitro, as well as norovirus in a 
cell-based replicon system. In an attempt to identify suitably-functionalized dipeptidyl 
transition state inhibitors that possess potent pharmacological activity, as well as 
molecular properties that are important for oral bioavailability and favorable ADMET 
characteristics,18-24 we describe herein for the first time the synthesis of bisulfite adducts 
of transition state inhibitors and their subsequent utilization in the inhibition of norovirus 
3CLpro in vitro, as well as viral replication in a  cell-based replicon system (Figure 1). To 
the best of our knowledge, this is the first report on the use of bisulfite adducts of 
transition state inhibitors to inhibit a protease. We furthermore describe the results of 
preliminary structure-activity relationship studies related to the probing of the S2 
subsite25 of norovirus 3CLpro, as well as the nature of the “cap” that projects toward the 
S3 subsite and beyond. 
                                                    [Figure 1] 
   The synthesis of dipeptidyl inhibitors 6a-j, 7a-j, 9, and 10 is summarized in Scheme 1. 
                                                   [Scheme 1] 
Reaction of an appropriate amino acid ester hydrochloride with trichloromethyl 
chloroformate yielded the corresponding isocyanate which was subsequently reacted 
with an appropriate alcohol in the presence of triethylamine to yield carbamate 
derivative 2. Hydrolysis with lithium hydroxide in aqueous THF followed by coupling with 
a glutamine surrogate26 yielded ester 4 which was further elaborated to yield aldehydes 
6a-j via sequential reduction to the alcohol with lithium borohydride, followed by Dess-
Martin oxidation.27 The reaction of aldehyde 6 (R1 = benzyl, R2 = isobutyl) with 
cyclopropyl isonitrile/HOAc followed by treatment with potassium carbonate in aqueous 
methanol yielded alcohol 8 which was then oxidized to the corresponding α-ketoamide 9 
using Dess-Martin reagent. The generated aldehyde and α-ketoamide bisulfite adducts  
were readily obtained by stirring aldehydes 6a-j and α-ketoamide 9 with sodium 
bisulfite.28  The interaction of the generated compounds with norovirus 3CLpro was 
investigated in vitro as previously described.16-17 The activity of the compounds against 
norovirus was also investigated in a cell-based system29-33 and the combined results are 
listed in Table 1.   
                                              [Table 1] 
   The rationale underlying the studies described herein rested on the following 
considerations: (a) bisulfite adducts of amino acid-derived isocyanates are readily-
accessible, stable, water-soluble solids which function as latent isocyanates. These 
adducts have been shown to be highly effective, time-dependent, irreversible inhibitors 
of mammalian serine proteases, such as neutrophil elastase, cathepsin G, and 
proteinase 3;34 (b) bisulfite adducts of aldehydes, methyl or cyclic ketones, and α-
ketoesters are readily-synthesized, stable solids having high aqueous solubility. 
Treatment of the addition products with acid or base yields the precursor carbonyl 
compounds;35 (c) we hypothesized that the bisulfite adducts of transition state (TS) 
inhibitors of proteases (serine and cysteine), such as peptidyl aldehydes, α-ketoamides, 
and others could potentially function as a latent form of the precursor TS inhibitor 
(Figure 1), generating the active form of the inhibitor in the gastrointestinal tract and 
blood plasma. In principle, the bisulfite adducts could also function as transition state 
mimics36 and, (d) the high aqueous solubility and pH-dependent equilibria between the 
precursor carbonyl compound and adduct were also envisaged to have a significant 
effect on potency and the ADMET and PK characteristics of the precursor TS inhibitors. 
It was envisioned that the bisulfite adducts might be suitable candidates for fulfilling 
such a role.  
   As shown in Table 1 the dipeptidyl aldehydes exhibited low to sub-micromolar 
inhibitory activity toward NV 3CLpro in vitro. The enzyme shows a strong preference for 
an R2 = isobutyl, which is in agreement with the known substrate specificity of the 
enzyme. The strong preference of NV 3CLpro for a P2 Leu is supported by substrate 
specificity studies using peptidyl p-nitroanilide substrates, as well as X-ray 
crystallographic studies.37  The results in Table 1 suggest that replacement of the 
isobutyl group by a cyclohexylmethyl group at R2 yields an inhibitor that is equipotent to 
6a (Table 1, compounds 6a and 6d). However, in sharp contrast to compound 6a, the 
ED50 of compound 6d was found to be an order of magnitude lower than that of 6a, 
presumably because of its better cellular permeability. The nature of the “cap” (R1) 
which projects toward the S3 pocket and beyond was briefly explored by replacing the 
benzyl group with meta- and para-fluorobenzyl, 2-phenylethyl, and 2-cyclohexylethyl. 
The m-fluorobenzyl and 2-cyclohexylethyl groups were equipotent to the benzyl group, 
and about 2-fold better than other substitutions (Table 1, compounds 6a, 6g, 6j versus 
6f and 6j).  
    The activity of the bisulfite adducts of the synthesized aldehydes was investigated in 
a cell-based system. The potency trends observed with the precursor aldehydes were 
generally reflected in the corresponding bisulfite salts, with bisulfite 7d (R2 = 
cyclohexylmethyl) being the most potent. In order to determine the nature of the active 
species, the behavior of aldehyde 6a and its corresponding bisulfite salt 7a was 
examined by mass spectroscopy. In separate experiments, compounds 6a and 7a were 
dissolved in dimethyl sulfoxide and diluted 1 to 1000 in either acetonitrile or water and 
examined by MS and tandem MS-MS. In acetonitrile the expected peaks for aldehyde 
6a were 404.4 M + H+ (dominant peak) and 426.3 M+Na. The mass spectra of bisulfite 
salt 7a using negative mode detection, showed a dominant peak at 484.5 for (M-1)-, a 
loss of H+ from the sulfonic acid moiety. Aldehyde 6a in aqueous solution showed peaks 
corresponding to the aldehyde (404.6), the aldehyde + sodium (426.4) and hydrated 
aldehyde + sodium (444.2) in positive mode. In water, bisulfite adduct 7a displayed a 
dominant peak at 484.5 in negative mode and the relative intensities of this parent ion 
and other ions remained unchanged over 24 hours (a time course study was carried 
out). In the case of 6a, the hydrated form was the dominant species after only five 
minutes exposure to water, while 7a remains unchanged as the bisulfite form after 24 
hours. The results indicate that the hydroxyl bisulfite functionality of 7a is stable in 
aqueous solution. In pH 7.4 buffer solution, however 7a gradually dissociates to the 
corresponding aldehyde 6a (results obtained from mass spectrometry study), which is in 
agreement with the results of X-ray crystallographic studies showing that incubation of 
bisulfite adduct 7a with norovirus 3CLpro in buffer solution results in the formation of an 
enzyme-aldehyde complex with the active site cysteine residue covalently bonded to the 
carbonyl carbon of aldehyde 6a.33  
    In summary, the utilization of bisulfite adducts of transition state inhibitors of serine 
and cysteine proteases in the in vitro and cell-based inhibition of norovirus 3CL 
protease has been described for the first time.  
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Table 1. Inhibitory activity of compounds 6, 7a-j, 9, 10 
 
 
 
  
 
aCC50: All compounds, except 6j and 7j, showed no toxicity up to 320 µM (CC50: > 
320µM). The CC50 values for 6j and 7j were 210 µM, and 240 µM, respectively. 
bNot determined (see text).    
Compounda R1 R2 R3 IC50 
(μM) 
ED50 
(μM) 
        6a benzyl Isobutyl CHO 0.6 0.2 
        7a benzyl Isobutyl CH(OH) SO3Na -b 0.3 
        6b benzyl n-propyl CHO 6.1 2.3 
        7b benzyl n-propyl CH(OH) SO3Na -b 1.5 
        6c benzyl n-butyl CHO 4.5 1.2 
        7c benzyl n-butyl CH(OH) SO3 Na -b 1.3 
        6d benzyl cyclohexylmethyl CHO 0.5 0.05 
        7d benzyl cyclohexylmethyl CH(OH) SO3 Na -b 0.06 
        6e benzyl benzyl CHO 5.1 1.8 
        7e benzyl benzyl CH(OH) SO3Na -b 1.1 
        6f p-fluorobenzyl Isobutyl CHO 1.8 0.5 
        7f p-fluorobenzyl Isobutyl CH(OH) SO3 Na -b 0.4 
        6g m-fluorobenzyl Isobutyl CHO 0.7 0.3 
        7g m-fluorobenzyl Isobutyl CH(OH) SO3Na -b 0.2 
        6h 2-phenylethyl Isobutyl CHO 1.9 1.1 
        7h 2-phenylethyl Isobutyl CH(OH) SO3Na -b 1.0 
        6j 2-cyclohexylethyl Isobutyl CHO 0.6 0.3 
        7j 2-cyclohexylethyl Isobutyl CH(OH) SO3 Na -b 0.3 
        917  3.4 1.1 
       10   5.3 0.8 
 Scheme 1 
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